EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical safety assessment of modified gamma globin lentiviral vector-mediated autologous hematopoietic stem cell gene therapy for hemoglobinopathies

Mohammad Shadid, Archana Shrestha, Punam Malik

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0306719 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Mohammad Shadid und 2 weiteren Autor:innen. Beteiligte Einrichtung: Aruvant Sciences, New York, NY, United States of America. Hauptthemen laut MEDLINE: Lentivirus, Genetic Therapy, Hematopoietic Stem Cell Transplantation, Genetic Vectors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Previously, we reported the development of a human A γ-globin gene lentivirus (LV), G b G, which expresses high levels of HbF to correct the sickle cell anemia (SCA) phenotype in the Berkeley SCA mouse model, and then modified the γ-globin gene by substituting glycine at codon 16 with aspartic acid in the A γ-globin gene to generate G b G M LV. In the present study, we evaluated the long-term safety of human A γ-globin gene carrying G b G M LV in wild-type mice after primary and secondary transplants of G b G M -modified hematopoietic stem cells (HSC) over 18 months. The safety of the G b G M bone marrow transplant was assessed by monitoring the effects on body weight, hematology, histopathology, malignancy formation, and survival. Mice transplanted with Mock-transduced and spleen focus forming virus (SFFV) γ-retroviral vector (RV)-transduced HSC served as negative and positive controls, respectively. The mean donor-cell engraftment was comparable across Mock, G b G M LV, and SFFV RV groups. There were no significant differences in body weight, clinical signs, immunophenotype, or histopathology in the G b G M -treated mice compared to controls. Four SFFV RV-treated mice, but none of the G b G M -treated mice, developed donor-derived, vector-positive lymphomas as demonstrated by flow cytometry analysis and in situ hybridization. These results highlight the safety of the administration of G b G M LV-modified HSC with long-term follow-up after primary and secondary transplants in mice. This data supported the initiation of phase 1/2 first-in-human SCA clinical trial in the United States.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LentivirusGenetic TherapyHematopoietic Stem Cell TransplantationGenetic Vectorsgamma-GlobinsHemoglobinopathiesAnimalsMiceHumansHematopoietic Stem CellsTransplantation, AutologousDisease Models, Animal

Substanzen

gamma-Globins

Autor:innen und Institutionen

  • Aruvant Sciences, New York, NY, United States of America.
  • Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States of America.
  • Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States of America.

Zitieren

APA

Shadid, M., Shrestha, A., & Malik, P. (2024). Preclinical safety assessment of modified gamma globin lentiviral vector-mediated autologous hematopoietic stem cell gene therapy for hemoglobinopathies. PLOS ONE. https://doi.org/10.1371/journal.pone.0306719

Vancouver

Shadid M, Shrestha A, Malik P. Preclinical safety assessment of modified gamma globin lentiviral vector-mediated autologous hematopoietic stem cell gene therapy for hemoglobinopathies. PLOS ONE. 2024. doi:10.1371/journal.pone.0306719

BibTeX
@article{Shadid2024,
  author = {Shadid, Mohammad and Shrestha, Archana and Malik, Punam},
  title = {Preclinical safety assessment of modified gamma globin lentiviral vector-mediated autologous hematopoietic stem cell gene therapy for hemoglobinopathies},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0306719}
}
Kostenlos starten →